{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-26-052527","form_type":"8-K","ticker":"PCRX","cik":"0001396814","company_name":"Pacira BioSciences, Inc.","filed_at":"2026-08-04T20:03:32+00:00","discovered_at":"2026-08-04T20:05:02.728163+00:00","generated_at":"2026-08-04T20:05:31.284502+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Pacira Q2 revenue $192.4M (+6% YoY); divests iovera° to Zimmer Biomet for up to $140M","bullets":["Q2 total revenue $192.4M (+6% YoY); GAAP net income $4.7M ($0.12 EPS) vs net loss of $4.8M in Q2 2025.","EXPAREL net sales $147.8M (+3% YoY); ZILRETTA $32.6M (+4%); iovera $6.8M (+22%).","Completed divestiture of iovera° to Zimmer Biomet for up to $140M ($70M upfront + milestones); closed July 31, 2026.","UnitedHealthcare now provides separate reimbursement for EXPAREL, covering ~40M lives.","Updated FY2026 total revenue guidance to $735M-$760M (from $745M-$770M) reflecting iovera divestiture."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-26-052527","json":"https://secwatch.observer/filing/0001628280-26-052527.json","markdown":"https://secwatch.observer/filing/0001628280-26-052527.md","text":"https://secwatch.observer/filing/0001628280-26-052527.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1396814/000162828026052527/0001628280-26-052527-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1396814/000162828026052527/pcrx-20260804.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-04T20:05:31.284502+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}